Table 4.
Summary of the main findings.
| ApoE2/4 lipid/lipoprotein level (or risk) compared to | |||||
|---|---|---|---|---|---|
| ApoE 2/2 | ApoE 2/3 | ApoE 3/3 | ApoE 3/4 | ApoE 4/4 | |
| TG | Lower | — | Higher | — | — |
| Total C | — | — | — | — | — |
| LDL-C | Higher1 | — | — | — | — |
| HDL-C | — | — | — | — | — |
| VLDL-C | Lower | — | — | — | — |
| VLDL-TG | Lower | — | — | — | — |
| LDL-TG | — | — | — | — | — |
| HDL-TG | — | — | — | — | — |
| Total ApoB | Higher | — | — | — | — |
| TG > 1.7 mmol/L | Lower | — | Higher | — | — |
| LDL-C > 3.4 | — | — | Higher | — | Lower |
| HDL-C < 0.9 mmol/L | — | — | — | — | — |
| Non-HDL-C > 4.2 mmol/L | — | — | — | — | Lower |
| Total C/HDL-C. > 5 | — | Higher | Higher | — | — |
| VLDL-C/TG > 0.5 | Lower | — | Higher | Higher | — |
Present is a summary of the lipid/lipoprotein differences between ApoE2/4 carriers and the other genotypes. Lower means that ApoE2/4 carriers present a lower level (or risk) than the selected genotype while higher means that ApoE2/4 carriers present a higher level (or risk) than the selected genotype. This summary is based on Table 2 and Figures 1 and 2.
Note: ApoB: apolipoprotein B-100 measured on delipidated plasma; C: cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglycerides
1The difference between ApoE2/2 and ApoE2/4 for LDL-C only reached significance when measured after ultracentrifugation.